Merck Gets FDA OK for Keytruda/Inlyta Combo in Renal Cell Carcinoma
April 22 2019 - 6:31AM
Dow Jones News
By Colin Kellaher
Merck & Co. (MRK) on Monday said the U.S. Food and Drug
Administration approved its cancer drug Keytruda in combination
with Pfizer Inc.'s (PFE) Inlyta for the first-line treatment of
patients with advanced renal cell carcinoma, the most common type
of kidney cancer.
The Kenilworth, N.J., drug maker said the approval is based on
findings from a phase 3 study that showed significant improvements
in overall survival, progression-free survival and objective
response rate for the combination compared to sunitinib, a
chemotherapy drug marketed by Pfizer as Sutent.
Merck said the approval marks the first indication in advanced
renal cell carcinoma for Keytruda, a cancer drug that harnesses a
patient's immune systems to fight tumors.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 22, 2019 07:16 ET (11:16 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2024 to May 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From May 2023 to May 2024